Residency · Residency · Urology

Anticoagulation and Antiplatelet Management in Urologic Surgery

Introduction

Managing patients on anticoagulant and antiplatelet therapy during the perioperative period presents a frequent and critical challenge in urologic surgery. Urologic procedures inherently carry an elevated risk of bleeding due to the highly vascular nature of the target organs and the difficulty in achieving hemostasis within the urinary tract lumen. Therefore, it is essential to balance the risk of perioperative hemorrhage against the risk of thromboembolic events. This balance requires a systematic, evidence-based approach that takes into account the bleeding risk specific to the procedure, the patient's individual thromboembolic risk, and the pharmacologic properties of the anticoagulant or antiplatelet agents involved.

Pharmacology of Anticoagulant and Antiplatelet Agents

Antiplatelet Agents

Aspirin (ASA) functions as an irreversible inhibitor of cyclooxygenase-1 (COX-1), and its antiplatelet effect lasts for the lifespan of the platelet, approximately 7 to 10 days. Clopidogrel (Plavix) is an irreversible antagonist of the P2Y12 receptor on platelets, with its effect persisting for 5 to 7 days. Prasugrel (Effient) is also an irreversible P2Y12 antagonist but is more potent than clopidogrel, with its effect lasting 7 to 10 days. Ticagrelor (Brilinta), in contrast, is a reversible P2Y12 antagonist, and its antiplatelet effect resolves within 3 to 5 days. Dual antiplatelet therapy (DAPT), which combines aspirin with a P2Y12 inhibitor, is commonly used after coronary stent placement to prevent stent thrombosis.

Anticoagulant Agents

Warfarin is a vitamin K antagonist that inhibits the synthesis of clotting factors II, VII, IX, and X. Its anticoagulant effect is monitored by the international normalized ratio (INR), and it has a half-life of 36 to 42 hours, requiring 5 to 7 days to clear from the system. Direct oral anticoagulants (DOACs) include dabigatran (Pradaxa), a direct thrombin inhibitor with a half-life of 12 to 17 hours and renal clearance dependence; rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Savaysa), all factor Xa inhibitors with half-lives ranging from 5 to 15 hours depending on the agent. Heparin, specifically unfractionated heparin (UFH), has a short half-life of 1 to 2 hours and can be reversed with protamine sulfate. Low-molecular-weight heparin (LMWH), such as enoxaparin, has a half-life of 4 to 5 hours and is only partially reversible with protamine.

Reversal Agents

Vitamin K is used to reverse warfarin effects, with reversal occurring over 12 to 24 hours; intravenous administration results in a faster onset. Fresh frozen plasma (FFP) and prothrombin complex concentrate (PCC, e.g., Kcentra) provide immediate warfarin reversal. Idarucizumab (Praxbind) is a specific reversal agent for dabigatran, while andexanet alfa (Andexxa) reverses the effects of factor Xa inhibitors such as rivaroxaban and apixaban. Platelet transfusion is employed to reverse antiplatelet agents in cases of life-threatening bleeding. Desmopressin (DDAVP) enhances platelet adhesion and serves as a useful adjunct in managing uremic bleeding.

<image>Pharmacology diagram showing the coagulation cascade with labeled sites of action for each anticoagulant class (warfarin on vitamin K-dependent factors, DOACs on thrombin or factor Xa, heparin on antithrombin III) and the platelet activation pathway with aspirin blocking COX-1 and P2Y12 inhibitors blocking ADP receptor</image>

Bleeding Risk Stratification of Urologic Procedures

Urologic procedures can be stratified into low, moderate, and high bleeding risk categories to guide anticoagulation management.

Low bleeding risk procedures include diagnostic cystoscopy, ureteral stent placement or removal, urodynamic studies, and minor penile or scrotal surgeries such as circumcision and hydrocelectomy. These procedures can generally be performed without stopping anticoagulation or antiplatelet therapy.

Moderate bleeding risk procedures encompass ureteroscopy with lithotripsy, laparoscopic or robotic nephrectomy, inguinal and pelvic lymph node dissection, and penile prosthesis implantation. In these cases, holding anticoagulants should be considered, although aspirin may often be continued.

High bleeding risk procedures include transurethral resection of the prostate (TURP), transurethral resection of bladder tumor (TURBT), percutaneous nephrolithotomy (PCNL), radical prostatectomy (open or robotic), partial nephrectomy, radical cystectomy, and renal biopsy. For these procedures, all anticoagulants and antiplatelet agents should be discontinued preoperatively to minimize bleeding risk.

Perioperative Management Protocols

Warfarin Management

For patients at low thromboembolic risk—such as those with atrial fibrillation without prior stroke and a CHA2DS2-VASc score of 4 or less—warfarin should be stopped five days before surgery without bridging anticoagulation. In contrast, patients at high thromboembolic risk—such as those with mechanical heart valves, recent venous thromboembolism (VTE) within three months, or a CHA2DS2-VASc score of 7 or higher—should stop warfarin five days preoperatively and receive bridging with low-molecular-weight heparin (LMWH). The bridging protocol involves initiating therapeutic LMWH three days after stopping warfarin, with the last dose administered 24 hours before surgery. Warfarin can be resumed on postoperative day one if hemostasis is adequate, and bridging anticoagulation should be restarted 24 to 48 hours postoperatively in high-risk patients. The BRIDGE trial demonstrated that forgoing bridging in most atrial fibrillation patients was non-inferior for preventing thromboembolism and resulted in significantly less major bleeding.

DOAC Management

Management of direct oral anticoagulants is generally simpler than warfarin due to their shorter half-lives and predictable pharmacokinetics. For low bleeding risk procedures, DOACs should be held for 24 hours before surgery. For high bleeding risk procedures, they should be held for 48 to 72 hours. In patients taking dabigatran with creatinine clearance below 50 mL/min, the hold period should be extended to 3 to 5 days because of renal clearance dependence. Bridging with LMWH is not necessary for DOACs because of their rapid onset of action upon resumption. Resumption of DOACs typically occurs 48 to 72 hours postoperatively for high-risk bleeding procedures.

Antiplatelet Management

Aspirin monotherapy can be continued for low and moderate bleeding risk procedures but should be held for 7 to 10 days before high-risk procedures. Clopidogrel monotherapy should be held for 5 to 7 days before moderate and high-risk procedures. In patients on dual antiplatelet therapy (DAPT) after coronary stent placement, the timing of elective surgery depends on the type of stent. For bare metal stents, a minimum of 4 to 6 weeks of DAPT is recommended before elective surgery. For drug-eluting stents, at least 6 months, ideally 12 months, of DAPT should be completed. If surgery cannot be delayed, aspirin should be continued while holding the P2Y12 inhibitor, and cardiology consultation is essential. It is critical never to discontinue both agents simultaneously in patients with recent coronary stents, as this poses a life-threatening risk of acute stent thrombosis.

<image>Decision algorithm flowchart for perioperative anticoagulation management in urologic surgery, showing the initial step of procedure bleeding risk stratification (low/moderate/high), followed by patient thromboembolic risk assessment, leading to specific recommendations for warfarin (with and without bridging), DOAC, and antiplatelet agent management including timing of cessation and resumption</image>

Special Considerations in Urology

Postoperative bleeding following TURP and TURBT can be delayed, occurring 7 to 14 days after surgery when the eschar sloughs. Therefore, it may be advisable to delay restarting anticoagulation until after this high-risk period when feasible. Continuous bladder irrigation (CBI) may be necessary to prevent clot retention during this time. Coordination with cardiology is important to determine an acceptable delay in anticoagulation resumption.

Percutaneous renal access procedures such as PCNL and renal biopsy carry the highest bleeding risk among urologic surgeries. Complete normalization of coagulation parameters is mandatory before these procedures. Additionally, interventional radiology should be readily available for selective renal artery embolization if significant bleeding occurs.

Shockwave lithotripsy (SWL) is contraindicated in patients on anticoagulation due to the risk of renal or perinephric hematoma. Aspirin should be held for 7 to 10 days before SWL, and anticoagulation must be fully reversed prior to the procedure.

Multidisciplinary Communication

Effective management requires involving cardiology for patients with mechanical heart valves, recent coronary stents, or recent venous thromboembolism. Shared decision-making with the patient is essential to balance the risks of bleeding and thrombosis. The perioperative plan should be clearly documented, specifying drug names, stop dates, and resumption plans. Hematology consultation should be considered for patients with complex coagulopathies or those on multiple anticoagulant and antiplatelet agents.

Key Clinical Pearls

The BRIDGE trial established that bridging anticoagulation is unnecessary for most atrial fibrillation patients on warfarin undergoing surgery, as bridging increases bleeding risk without reducing thromboembolic events. DOACs do not require bridging due to their rapid onset and offset of action. Procedures such as TURP and TURBT are classified as high bleeding risk primarily because of the inability to achieve hemostasis on the resection bed and the risk of delayed hemorrhage. It is critical never to discontinue both components of dual antiplatelet therapy simultaneously in patients with coronary stents without cardiology guidance. Management should be guided by the specific bleeding risk of the procedure rather than adopting a one-size-fits-all approach.

References

1. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373(9):823-833.
2. Culkin DJ, Exaire EJ, Green D, et al. Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper. J Urol. 2014;192(4):1026-1034.
3. Violette PD, Vernooij RW, Bhatt DL, et al. A systematic review of perioperative antiplatelet and anticoagulant management for urological procedures. Eur Urol. 2021;79(6):1-15.
4. Spyropoulos AC, Brohi K, Chen J, et al. Scientific and Standardization Committee Communication: guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy. J Thromb Haemost. 2019;17(11):1966-1974.

Read this lecture as Markdown